Table 3. . Primary adjusted analysis and fully adjusted model for overall survival, progression-free survival and time to next treatment.
| Outcome/analysis | Median (95% CI) MajesTEC-1 |
Median (95% CI) RWPC |
HR (95% CI) | p-value |
|---|---|---|---|---|
| OS | ||||
| Unadjusted | 18.27 (15.08–NR) | 13.83 (12.32–15.67) | 0.77 (0.58–1.02) | 0.070 |
| Primary analysis | 18.27 (15.08–NR) | 14.46 (12.29–18.56) | 0.82 (0.59–1.14) | 0.233 |
| Fully adjusted model | 18.27 (15.08–NR) | 13.67 (11.30–18.92) | 0.79 (0.54–1.15) | 0.220 |
| PFS | ||||
| Unadjusted | 11.30 (8.77–17.15) | 3.91 (3.48–4.30) | 0.42 (0.33–0.53) | <0.0001 |
| Primary analysis | 11.30 (8.77–17.15) | 3.65 (3.09–4.30) | 0.43 (0.33–0.56) | <0.0001 |
| Fully adjusted model | 11.30 (8.77–17.15) | 3.38 (2.92–4.30) | 0.41 (0.31–0.55) | <0.0001 |
| TTNT | ||||
| Unadjusted | NR (12.68–NR) | 5.19 (4.63–5.75) | 0.34 (0.26–0.45) | <0.0001 |
| Primary analysis | NR (12.68–NR) | 4.90 (4.07–5.88) | 0.36 (0.27–0.49) | <0.0001 |
| Fully adjusted model | NR (12.68–NR) | 4.40 (3.55–5.72) | 0.37 (0.26–0.51) | <0.0001 |
HR: Hazard ratio; NR: Not reached; OS: Overall survival; PFS: Progression-free survival; RWPC: Real-world physician’s choice; TTNT: Time to next treatment.